A new drug jointly developed by Japanese and UK pharmaceutical companies targets HER2-positive breast cancers. It consists of a powerful chemotherapy drug linked to an antibody. In a clinical study, cancer shrank or disappeared in 60 percent of subjects. We also introduce care for patients struggling with changes in appearance due to treatment, and a cheerdance team made up of cancer survivors. The program looks at not just treatment, but ways to cope with the disease.